UNMC testing new oral drug to prevent COVID-19
UNMC is apart of an international clinical trial to test the new drug, Molnupirvir.
LINCOLN, Neb. (KLKN) – The University of Nebraska Medical Center begins a new clinical research trial testing a new oral antiviral drug that can prevent COVID-19.
The trial evaluates the effectiveness and safety of the new drug, Molnupirvir.
According to UNMC, Molnupiravir demonstrated an ability to prevent the growth of the virus that causes COVID-19 in preclinical studies.
Dr. Diana Florescu, professor in the UNMC Department of Internal Medicine and an infectious diseases specialist at Nebraska Medicine, is directing the clinical trial.
“For many years, antivirals such as this drug, have been effective in preventing illness after exposure to a variety of pathogens and to reduce the risk of spreading the infection to close contacts,” said Dr. Florescu.
UNMC says about 1,300 participants will be recruited for the study.
The trial lasts about one month from the time the participant provides the needed documented consent, according to UNMC.